Advances in Pharmacoepidemiology and Drug Safety

Audra L Stinchcomb

Audra L Stinchcomb, PhD
Professor, School of Pharmacy
University of Maryland, Baltimore, MD 21201, USA

Biography

Dr. Audra L. Stinchcomb obtained her Ph.D. in Pharmaceutics in 1995 from The University of Michigan College of Pharmacy. In April 2001 she joined the Department of Pharmaceutical Sciences at the University of Kentucky College Of Pharmacy in Lexington, KY.  Audra was promoted to Associate Professor with tenure on January 1, 2005.
Her research work involves the design and testing of novel prodrugs and codrugs for transdermal delivery, as well as intranasal delivery, testing of novel materials for transdermal patches, development of bioanalytical methods to determine topical bioequivalence, and cannabinoid drug delivery optimization. Dr. Stinchcomb holds several issued patents, and is the founder of the specialty pharmaceutical company AllTranz Inc.  Her research work has brought in over $3,000,000 in funding from federal (NIH and private foundations) and industrial sources.
She participates as a reviewer for SBIR/STTR NIH and NSF Study Sections, “Drug Discovery and Delivery” and Neuroscience. She serves as a reviewer for over twenty pharmaceutical and drug delivery journals, and is on the editorial advisory board of Pharmaceutical Research and the Journal of Pharmaceutical Sciences.  Dr. Stinchcomb has served as a member of the United States Pharmacopeia, an Institutional Review Board for clinical research, and as a scientific advisor for the EPA and NIOSH.  She is currently a member of the American Association of Pharmaceutical Scientists, the Controlled Release Society, and the International Cannabinoid Research Society, and also holds a pharmacy license in the state of Colorado.

Research Interest

1) To improve pharmacotherapy for alcohol and tobacco addiction recovery by creating a transdermal codrug dosage form 
2) To increase understanding of the transdermal codrug as a viable drug-delivery option for other therapies. A codrug or mutual prodrug consists of two synergistic drugs chemically linked together, in order to improve the drug delivery properties of one or both drugs. Transdermal prodrugs and drug combination patches are extensively studied, and a practical augmentation of these two delivery options is the transdermal codrug.